NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Price Target & More

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.57. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Dicerna Pharmaceuticals.

7 brokers have issued twelve-month target prices for Dicerna Pharmaceuticals' shares. Their predictions range from $10.00 to $17.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $14.20 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price. View Analyst Ratings for Dicerna Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Dicerna Pharmaceuticals saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 4,192,190 shares, an increase of 144.6% from the June 15th total of 1,713,672 shares. Based on an average trading volume of 1,144,343 shares, the short-interest ratio is presently 3.7 days. Approximately 10.5% of the shares of the stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Clovis Oncology (CLVS), Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK) and Prestige Brands (PBH).

Press coverage about DRNA stock has been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 47.56 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Dicerna Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.14%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $12.48.

Dicerna Pharmaceuticals has a market capitalization of $660.27 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]